Why You Don't Need to Cycle CJC-1295 or Tesamorelin

The standard advice in peptide communities is to run CJC-1295 and Ipamorelin for three months, take one month off, and repeat. That advice is not wrong, but the reason behind it is more specific than most people realize, and understanding the actual reason changes how you think about these compounds entirely.

Start with the basic system. Your body releases growth hormone in pulses, and those pulses are controlled by two separate signals coming from your hypothalamus. The first is something called GHRH, or growth hormone releasing hormone, which is the primary accelerator. It binds to GHRH receptors on your pituitary and tells it to release growth hormone. The second signal runs through a completely different receptor called the ghrelin receptor, and compounds that activate this pathway amplify the GHRH signal and add their own independent push on top of it. CJC-1295 and tesamorelin mimic GHRH and work through the first receptor. Ipamorelin is a ghrelin mimetic and works through the second. Same vial, totally different locks.

That distinction matters because these two receptor systems do not behave the same way under continuous stimulation.

When you activate the ghrelin receptor repeatedly, the body starts a process called beta-arrestin mediated internalization, which is essentially the cell pulling its own receptors off the surface and moving them inside so they can no longer receive the signal. Think of it like a loading dock that gets overwhelmed and starts locking its own doors. The receptors are still there, they are just no longer accessible. The effect accumulates over time. A 16-week human trial tracked what happens to growth hormone response under continuous ghrelin receptor stimulation, and by week 16, the response had dropped approximately 45 percent from baseline. That is not a minor attenuation. That is nearly half the signal gone. When subjects stopped for four weeks, response returned fully to where it started. So the desensitization is real, it is clinically measurable, and it is reversible with adequate time off. That is the actual scientific basis for cycling Ipamorelin.

Now look at what happens on the GHRH side.

Tesamorelin was given as a daily injection to HIV patients for 52 consecutive weeks in the Phase 3 trials that led to its FDA approval, and IGF-1 levels remained elevated and stable the entire time with no meaningful decline. An earlier trial by Falutz and colleagues ran daily tesamorelin for 26 weeks and found the same thing, sustained IGF-1 elevation without attenuation. These are not short observations. Fifty-two weeks of daily dosing with no receptor dropout is a different outcome than what you see with continuous ghrelin receptor stimulation, and it suggests the GHRH receptor system is not experiencing the same internalization problem.

The reason is likely in the pharmacokinetics. Tesamorelin has a half-life of roughly 30 minutes. You inject it, it peaks, it signals the pituitary, and it clears. Within about 30 minutes, circulating levels are already falling, and by the time the next daily dose arrives more than 23 hours later, the receptors have had essentially a full day to recover, recycle back to the surface, and reset. The signal is brief and the recovery window is long. That is a fundamentally different exposure pattern than what ghrelin receptors experience with Ipamorelin dosing, where the receptor is being activated multiple times per day with less time between exposures to recover.

The independence between these two systems is not just theoretical. Research using perifused rat pituitary cells directly demonstrated that desensitizing the GHRH receptor has no effect on the ghrelin receptor's function, and desensitizing the ghrelin receptor has no effect on the GHRH receptor's function. They do not cross-desensitize. What happens to one system does not drag the other one down. This is what makes the combination approach make sense mechanically: you can have ghrelin receptor desensitization accumulating on one side while the GHRH receptor system continues operating normally on the other.

There is also supporting data from the ghrelin side that clarifies the timeline question. MK-677, which is an oral ghrelin mimetic and therefore activates the same receptor pathway as Ipamorelin, maintained elevated GH and IGF-1 for two full years of continuous use in one study of healthy older adults. That appears to contradict the desensitization concern, but there is an important distinction: the degree of receptor internalization likely depends on the depth and frequency of stimulation, and the absolute growth hormone levels seen with MK-677 in that population were modest. Partial or mild stimulation of the ghrelin receptor may not drive enough internalization to produce the 45 percent decline seen when the receptor is pushed harder. The Hexarelin data that showed significant desensitization used a potent ghrelin receptor agonist at doses designed to produce substantial GH output. The variable is probably stimulus intensity, not simply which receptor is being activated.

So the practical takeaway is straightforward. If you are running CJC-1295 with Ipamorelin, you cycle the protocol because of the Ipamorelin. The ghrelin receptor needs time off to recover its surface density and restore full responsiveness. Three months on, one month off is a reasonable structure based on the available data showing full recovery within four weeks of stopping. The CJC component does not require that break based on anything in the published literature, but since you are cycling the combination anyway, both compounds go on the same schedule by default.

If you are running tesamorelin alone, there is no published clinical evidence suggesting you need to cycle it at all. The 52-week sustained efficacy data is the longest continuous human trial available for any GHRH analog, and it shows no receptor attenuation over that period.

Most cycling advice in this space was built around the weakest link in the protocol and then applied to everything in the vial. That works as a precaution, but it obscures the actual mechanism, and when you understand the actual mechanism, you understand exactly what you are protecting against and what you are not.

---

References

1. Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8 Suppl B:141-143 — 16-week human trial showing 45% GH response decline with continuous ghrelin receptor stimulation, full recovery after 4 weeks off. Source
2. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin daily dosing for 26 weeks with sustained IGF-1 elevation. Source
3. FDA Prescribing Information. EGRIFTA (tesamorelin). 2010/2025 — 52-week pooled Phase 3 data showing sustained IGF-1 and VAT reduction through week 52
4. Blake AD, Smith RG. Desensitization studies using perifused rat pituitary cells. J Endocrinol. 1991;1291:11-19 — Proved GHRH and ghrelin receptor systems are independent with no cross-desensitization. Source
5. Nass R et al. Effects of an oral ghrelin mimetic on body composition in healthy older adults. Ann Intern Med. 2008;1499:601-611 — MK-677 ghrelin mimetic maintained GH/IGF-1 elevation for 2 years of continuous use. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness